Avior Wealth Management LLC Has $280,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Avior Wealth Management LLC cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,818 shares of the company’s stock after selling 279 shares during the quarter. Avior Wealth Management LLC’s holdings in Moderna were worth $280,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Moderna by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company’s stock worth $2,856,841,000 after acquiring an additional 196,012 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Moderna by 1.3% during the 1st quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company’s stock worth $957,063,000 after acquiring an additional 77,265 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Moderna by 9.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after acquiring an additional 476,201 shares during the last quarter. Morgan Stanley increased its holdings in shares of Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after acquiring an additional 670,284 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after acquiring an additional 1,690,341 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MRNA has been the topic of a number of recent analyst reports. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. HSBC restated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, Canaccord Genuity Group boosted their price target on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus target price of $126.49.

Moderna Price Performance

NASDAQ:MRNA opened at $101.41 on Friday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $144.43. The stock has a fifty day moving average price of $100.63 and a 200-day moving average price of $93.64.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same period in the prior year, the company earned $3.61 EPS. Moderna’s revenue for the quarter was down 44.9% on a year-over-year basis. As a group, research analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current year.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the transaction, the director now directly owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The disclosure for this sale can be found here. Insiders sold a total of 109,954 shares of company stock valued at $11,533,976 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.